Results 261 to 270 of about 45,621 (284)

Identification of New Human CYP2C19 Alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian Poor Metabolizer of Mephenytoin

The Journal of Pharmacology and Experimental Therapeutics, 1998
A genetic polymorphism in the metabolism of the anticonvulsant drug S-mephenytoin has been attributed to defective CYP2C19 alleles. This genetic polymorphism displays large interracial differences with the poor metabolizer (PM) phenotype representing 2-5% of Caucasian and 13-23% of Oriental populations.
G C, Ibeanu, J A, Goldstein, U, Meyer, S, Benhamou, C, Bouchardy, P, Dayer, B I, Ghanayem, J, Blaisdell   +7 more
openaire   +2 more sources

CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association

Circulation
There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are used to prevent ischemic outcomes in common diseases such as coronary and peripheral arterial disease and stroke.
Naveen L. Pereira, Sharon Cresci, D. Angiolillo, Wayne Batchelor, Q. Capers, Larisa H. Cavallari, Dana Leifer, Jasmine A. Luzum, D. M. Roden, K. Stellos, Stephanie L. Turrise, S. Tuteja   +11 more
semanticscholar   +1 more source

The CYP2C19 Enzyme Polymorphism

Pharmacology, 2000
The genetic test is gradually replacing probe drugs as the primary tool for screening populations for the CYP2C19 polymorphism. A full appreciation for the clinical and toxicological relevance of this genetic variation is presently limited. Further research is needed in several areas.
openaire   +2 more sources

Clopidogrel Inhibits CYP2C19‐Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms

The Journal of Clinical Pharmacology, 2009
This study explores the impact of clopidogrel on the pharmacokinetics of omeprazole related to CYP2C19 genetic polymorphisms. Twelve healthy volunteers (6 CYP2C19*1/*1, 5 CYP2C19*2/*2, and 1 CYP2C19*2/*3) are enrolled in a 2‐phase randomized crossover trial.
B L, Chen, Y, Chen, J H, Tu, Y L, Li, W, Zhang, Q, Li, L, Fan, Z R, Tan, D L, Hu, D, Wang, L S, Wang, D S, Ouyang, H H, Zhou   +12 more
openaire   +2 more sources

Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention

Arteriosclerosis, Thrombosis and Vascular Biology, 2019
Current guidelines recommend dual antiplatelet therapy—a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin—for patients undergoing percutaneous coronary intervention. Although clopidogrel is the most commonly prescribed P2Y12 inhibitor,
Melissa D. Klein, Alexis K. Williams, Craig R. Lee, G. Stouffer   +3 more
semanticscholar   +1 more source

Functional characterization of two novel CYP2C19 variants (CYP2C19*18andCYP2C19*19) found in a Japanese population

Xenobiotica, 2007
Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of a wide range of therapeutic drugs and exhibits genetic polymorphism with interindividual differences in metabolic activity. We have previously described two CYP2C19 allelic variants, namely CYP2C19*18 and CYP2C19*19 with Arg329His/Ile331Val and Ser51Gly/Ile331Val substitutions,
N. Hanioka, N. Hanioka, Y. Tsuneto, Y. Saito, T. Sumada, K. Maekawa, K. Saito, J. Sawada, S. Narimatsu   +8 more
openaire   +2 more sources

CYP2C19 genetic mutations in North Indians

Clinical Pharmacology & Therapeutics, 2000
To identify defective alleles of CYP2C19 (CYP2C19*2 and *3) in North Indians.One hundred extensive metabolizers and 21 poor metabolizers of omeprazole were genotyped with respect to CYP2C19*2 and *3 alleles with polymerase chain reaction-based diagnostic tests.Fifty-two extensive metabolizers and six poor metabolizers were homozygous with the CYP2C19*1/
J K, Lamba, R K, Dhiman, K K, Kohli
openaire   +2 more sources

Evaluation of CYP2C19 Genotype‐Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant

Clinical pharmacology and therapy, 2020
There is a high risk of voriconazole failure in those with subtherapeutic drug concentrations, which is more common in CYP2C19 (cytochrome P450 2C19) rapid/ultrarapid metabolizers (RMs/UMs).
J. Patel, Issam S. Hamadeh, Myra M. Robinson, Zainab Shahid, J. Symanowski, N. Steuerwald, A. Hamilton, E. Reese, Dragos C. Plesca, J. Arnall, Margaret Taylor, J. Trivedi, M. Grunwald, Jonathan M Gerber, N. Ghosh, B. Avalos, E. Copelan   +16 more
semanticscholar   +1 more source

Clopidogrel, CYP2C19, and a Black Box

The Journal of Clinical Pharmacology, 2013
AbstractIt has been presumed that CYP2C19 has a major role in the metabolism of clopidogrel. This presumption has been based on in vitro drug metabolism studies using microsomes from baculovirus infected insect cells (BD‐Supersomes™). If clopidogrel were primarily a CYP2C19 substrate, a drug/drug interaction with CYP2C19 inhibitors, such as proton pump
Neville F, Ford, Dirk, Taubert
openaire   +2 more sources